REFERENCES
1. Howlander N, Noone Am, Krapcho M, Neyman N, etal. (eds.) SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
2. National Institute of Dental & Craniofacial Research. National Institutes of Health. Oral complications of cancer treatment: what the dental team can do. Date last modified March 25, 2011. Available at: www.nidcr.nih.gov/OralHealth/Topics/CancerTreatment/OralComplicationsCancerOral.htm. Accessed September 4, 2011.
3. Campaign targets oral complications of cancer treatment. January 1999. U.S> Department of Health and Human Services, National Institutes of Health, National Institute of Dental and Craniofacial Research Website. Available at http://www.nidcr.nih.gov/NewsAnd Reports/NewsReleases/News Release0111271999.htm. Accessed July 20,2011.
4. Hong, CHL, Napeñas JJ, Hodgson BD, Stokman MA, et al. A systematic review of dental disease in patients undergoing cancer therapy. Support Cancer Care 2010, August;18(8):1007-1021.
5. McClure D, Essary D, Gurenlian JR: A collaborative team approach for symptom management for head and neck cancer patients. Grand Rounds 2007;2(7):43-51.
6. The Oral Cancer Foundation web site. Oral Cancer Facts. Available at: http://oralcancerfoundation.org/facts/index/htm. Accessed June 28, 2011.
7. American Cancer Society. Chemotherapy principles: an in-depth discussion. Available at http://www.cancer.org. Accessed September 3, 2011.
8. The Cleveland Foundation. Cleveland Clinic Cancer Center. Chemotherapy drugs-drug names. Available at: www.chemocare.com. Accessed September 2, 2011.
9. Winn RL, Meiller TF, Crossley HL. Drug information handbook for dentistry, 15th ed. 2009. Hudson, Oh: Lexicomp.
10. Drugs.com. Drug information online. Available at:www.drugs.com. Accessed 9/3/11.
11. The Cleveland Foundation. Cleveland Clinic Cancer Center. Managing chemotherapy side effect. Available at www.chemocare.com. Accessed September 2, 2011.
12. Keefe DM, Schubert MM, Elting LS, Sonis ST, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007;109:820-831.
13. McGettigan S, Tompkins C. Managing mucositis in head and neck cancer patients undergoing radiation therapy. Community Oncology 2006;3:653-656.
14. Washington HV, Clarkson JE, Bryan G, Furness S, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment (Review). 2011, Issue 4. The Cochrane Collaboration. John Wiley & Sons. Available at http://www.thecochranelibrary.com. Accessed September 4, 2011.
15. National Cancer Institute: PDQ® Oral Complications of Chemotherapy and Head/Neck Radiation. Bethesda, MD: National Cancer Institute. Date last modified March 24, 2011. Available at: http://cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessional. Accessed July 20, 2011.
16. Lalla RV, Latortue MC, Hong CH, et al.: A systematic review of oral fungal infections in patients receiving cancer therapy. Support Cancer Care 2010; 18(8):985-992.
17. Ellis ME, Clink H, Ernst P, et al.: Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994;13(1):3-11.
18. Elad S, Zadik Y, Hewson I, et al: A systematic review of viral infection associated with oral involvement in cancer patient: a spotlight on Herpesviridea. Support Care Cancer 2010;18(8):993-1006.
19. Nicolatou-Galitis O, Athanassiadow P, Kouloulias V, et al. Herpes simplex virus-1 (HSV-1) infection in radiation induced oral mucositis. Support Care Cancer 2006;14:753-762.
20. Leflore S, Anderson PL, Fletcher CV: A risk-benefit evaluation of acyclovir for the treatment and prophylaxis of herpes simplex infections. Drug Saf 2000;23(2):131-142.
21. Reusser P: Management of viral infections in immunocompromised cancer patients. Swiss Med Wkly 2002;132(27-28):374-378.
22. Naesens L, De Clercq E: Recent developments in herpesvirus therapy. Herpes 2001;8(1):12-16.
23. Jublet B: Valacyclovir and famciclovir therapy in herpes zoster. Curr Neurol Neurosci Rep 2002;2(6):477-478.
24. Burns LJ, Miller W, Kandaswamy C, et al: Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogenic transplantation. Bone Marrow Transplant 2002;30(12):945-951.
25. Zaia JA: Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect Dis 2002;35(8):999-1004.
26. Peterson DE, Doerr W, Hovan A, et al.: Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies. Support Care Cancer 2010;18(8):1089-98.
27. Silverman S Jr: Complications of treatment. In Silverman S Jr, ed.: Oral Cancer. 5th ed. Hamilton, Canada: BC Decker Inc, 2003, pp.113-28.
28. Ripamonti C, Zecca E, Bruncelli C, et al.: A randomized controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer 1998;82(10):1938-1945.
29. Oral Cancer Self-Examination. Available at: http://www.floss.com/oral_cancer_self-test.htm. Accessed 9/4/11.
30. National Institute of Dental & Craniofacial Research, National Insitutes of Health. Detecting oral cancer: a guide for health care professionals. Bethesda, MD. Available at: www.nidcr.nih.gov. Accessed September 5, 2011.
31. Pacak DK. Developing a documentation protocol. Dimensions Dent Hyg. 2011. April;38-43.
Loading ...
